Abstract 468P
Background
Third-generation regimens with chemoradiotherapy has been established as one of a standard treatment in the phase III study WJTOG0105 even 10 years after starting treatment. We conducted an additional analysis by the histological type (Non-squamous [Non-Sq] vs. Squamous [Sq]) to examine differences of efficacy and patterns of initial failure.
Methods
Patients received the following treatments: MVP, mitomycin (8 mg/m2 on day 1, 29), vindesine (3 mg/m2 on day 1, 8, 29, 36), and cisplatin (80 mg/m2 on day 1, 29) with concurrent TRT (60 Gy), followed by 2 courses of MVP; IC, weekly irinotecan (20 mg/m2)/carboplatin (AUC 2) for 6 weeks with concurrent TRT (60 Gy), followed by 2 courses of irinotecan (50 mg/m2)/carboplatin (AUC 5); PC, weekly paclitaxel (40 mg/m2)/carboplatin (AUC 2) for 6 weeks with concurrent TRT (60 Gy), followed by 2 courses of paclitaxel (200 mg/m2)/carboplatin (AUC 5). Overall survival (OS), progression free survival (PFS), and patterns of initial failure were compared by the histological type.
Results
From September 2001 to September 2005, 440 patients (arm A, n = 146; arm B arm, n = 147; arm C, n = 147) were enrolled. The median follow-up time 140 months. The median OS and PFS were 23.5, 8.3 months in Non-Sq and 19.7, 8.3 months in Sq. The efficacy of PC and IC was compared with MVP in each histological type. For Non-Sq, the median OS and PFS were 25.1, 8.3 months in PC and 20.3, 8.3 months in IC and 25.2, 8.4 months in MVP. For Sq, the median OS and PFS were 20.5, 9.9 months in PC and 17.1, 7.8 months in IC and 19.4, 8.3 months in MVP. There was no statistically significant difference in OS and PFS between PC, IC and MVP in each histological type. In the patterns of initial failure, out-field recurrence rate in Non-Sq (51.1%) was higher than Sq (26.1%). Furthermore, the patterns of initial failure were similar between PC, IC and MVP.
Conclusions
Weekly PC with concurrent TRT showed similar efficacy to MVP with concurrent TRT, with no correlation to the histological type in 10-years follow-up with WJTOG0105. In the pattern of initiated failure, out-field recurrence in Non-Sq was tend to be higher than in Sq.
Clinical trial identification
Clinical trial information: 000030811.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
West Japan Oncology Group (WJOG).
Disclosure
M. Tsuboi: Honoraria (institution): Bristol-Myers Squibb. M. Satouchi: Honoraria (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Bristol-Myers Squibb. D. Fujimoto: Honoraria (self): Bristol-Myers Squibb. T. Hirashima: Honoraria (self): Bristol-Myers Squibb; Research grant / Funding (institution): Bristol-Myers Squibb. N. Yamamoto: Honoraria (self): Bristol-Myers Squibb; Research grant / Funding (institution): Bristol-Myers Squibb. K. Nakagawa: Honoraria (self): Bristol-Myers Squibb; Research grant / Funding (institution): Bristol-Myers Squibb. All other authors have declared no conflicts of interest.
Resources from the same session
41P - Clinical verification on the relationship between serum lipid metabolism and the immune microenvironment in breast cancer patients
Presenter: Wataru Goto
Session: Poster display session
Resources:
Abstract
42P - Genome wide copy number analysis of circulating tumour cells in breast cancer liver metastasis
Presenter: Saber Imani
Session: Poster display session
Resources:
Abstract
43P - A hotspot variants p.H1047R and p.H1047L in p110α/ΔNp63α complex affects structure, function and contributes to susceptibility metastatic breast cancer
Presenter: Zou Linglin
Session: Poster display session
Resources:
Abstract
44P - Correlation of circulating tumour cells with PET-CT in metastatic breast cancer
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract
45P - The challenge of evaluating new targeted therapies: Opportunities in stratifying the therapeutic response per tumour location
Presenter: Hubert Beaumont
Session: Poster display session
Resources:
Abstract
46P - Plasma soluble CD36 of breast cancer based on pathological and clinical characteristics
Presenter: Aditia Romadhoni
Session: Poster display session
Resources:
Abstract
47P - Investigation of the use of a novel S-1 administration method for treating metastatic and recurrent breast cancer
Presenter: MAYUKO MIKI
Session: Poster display session
Resources:
Abstract
48P - Development of MDA-MB-231-3D-Spheroid as a reliable model for studying Nav1.5 and nNav1.5-mediated breast cancer metastasis
Presenter: Ahmad Murtadha
Session: Poster display session
Resources:
Abstract
49P - Biochemical study on modifying role of variants of leptin gene and its receptor on serum leptin levels in breast cancer
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
50P - Prognostic factors of recurrence or distant metastasis in elderly breast cancer patients
Presenter: Seungju Lee
Session: Poster display session
Resources:
Abstract